Perioperative Considerations in Crohn Disease and Ulcerative Colitis

Abstract

The management of inflammatory bowel disease (IBD) is medically and surgically complex. Numerous patient- and disease-oriented factors must be considered in treating patients with IBD, including nutritional replenishment/support, effect of immunosuppressive medications, extent of resection, and use of proximal diversion. Perioperative planning and optimization of the patient is imperative to ensuring favorable outcomes and limiting morbidity. These perioperative considerations in Crohn disease and ulcerative colitis are reviewed here.

Keywords

Crohn disease - ulcerative colitis - perioperative management - steroids - immunomodulators - biologics - nutrition

• References

• 1 Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141 (1) 90-97
• 2 Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003; 134 (4) 565-572 , discussion 572–573
• 3 Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol 2007; 23 (4) 400-405
• 4 Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 2000; 43 (8) 1141-1145
• 5 Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007; 50 (3) 331-336
• 6 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14 (8) 1105-1111
• 7 Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am 2011; 91 (4) 787-803 , viii
• 8 Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn's disease. Aliment Pharmacol Ther 2014; 40 (9) 1009-1022
• 9 Larson DW, Lovely JK, Cima RR , et al. Outcomes after implementation of a multimodal standard care pathway for laparoscopic colorectal surgery. Br J Surg 2014; 101 (8) 1023-1030
• 10 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc 2011; 86 (8) 748-757
• 11 Furst MB, Stromberg BV, Blatchford GJ, Christensen MA, Thorson AG. Colonic anastomoses: bursting strength after corticosteroid treatment. Dis Colon Rectum 1994; 37 (1) 12-15
• 12 Tzivanakis A, Singh JC, Guy RJ, Travis SP, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in Crohn's disease surgery. Dis Colon Rectum 2012; 55 (5) 558-562
• 13 Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103 (9) 2373-2381
• 14 Mascarenhas C, Nunoo R, Asgeirsson T , et al. Outcomes of ileocolic resection and right hemicolectomies for Crohn's patients in comparison with non-Crohn's patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications. Am J Surg 2012; 203 (3) 375-378 , discussion 378
• 15 Sharma A, Chinn BT. Preoperative optimization of Crohn disease. Clin Colon Rectal Surg 2013; 26 (2) 75-79
• 16 Eriksen TF, Lassen CB, Gögenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis 2014; 16 (5) O154-O160
• 17 Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (7) 1610-1619
• 18 Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125 (2) 320-327
• 19 Mahadevan U, Loftus Jr EV, Tremaine WJ , et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8 (5) 311-316
• 20 Lichtenstein GR, Feagan BG, Cohen RD , et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107 (9) 1409-1422
• 21 Lichtenstein GR, Feagan BG, Cohen RD , et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 (5) 621-630
• 22 Colombel JF, Loftus Jr EV, Tremaine WJ , et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99 (5) 878-883
• 23 Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg 2009; 33 (5) 1049-1052
• 24 Fraser CG, Preuss FS, Bigford WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc 1952; 149 (17) 1542-1543
• 25 Beck DE, Opelka FG. Perioperative steroid use in colorectal patients. Results of a survey. Dis Colon Rectum 1996; 39 (9) 995-999
• 26 Zaghiyan K, Melmed GY, Berel D, Ovsepyan G, Murrell Z, Fleshner P. A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. Ann Surg 2014; 259 (1) 32-37
• 27 Hicks CW, Wick EC, Salvatori R, Ha CY. Perioperative corticosteroid management for patients with inflammatory bowel disease. Inflamm Bowel Dis 2015; 21 (1) 221-228
• 28 Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis 2011; 13 (11) 1294-1298
• 29 Pinna-Pintor M, Arese P, Bona R , et al. Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 2000; 43 (5) 609-613 , discussion 613–614
• 30 Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44 (10) 1436-1440
• 31 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg 2011; 15 (2) 267-276
• 32 Hanauer SB, Feagan BG, Lichtenstein GR , et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317) 1541-1549
• 33 Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12 (10) 1730-1736 , discussion 1736–1737
• 34 Marchal L, D'Haens G, Van Assche G , et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19 (7) 749-754
• 35 Nasir BS, Dozois EJ, Cima RR , et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg 2010; 14 (12) 1859-1865 , discussion 1865–1866
• 36 Waterman M, Xu W, Dinani A , et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013; 62 (3) 387-394
• 37 Myrelid P, Marti-Gallostra M, Ashraf S , et al. Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy. Br J Surg 2014; 101 (5) 539-545
• 38 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease—a nationwide cohort study. Aliment Pharmacol Ther 2013; 37 (2) 214-224
• 39 Appau KA, Fazio VW, Shen B , et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12 (10) 1738-1744
• 40 Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients. Am J Gastroenterol 2013; 108 (4) 583-593
• 41 Strong SA. Inflammatory bowel disease surgery in the biologic therapy era. Curr Opin Gastroenterol 2012; 28 (4) 349-353
• 42 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18 (16) 1861-1870
• 43 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51 (8) 1202-1207 , discussion 1207–1210
• 44 Selvasekar CR, Cima RR, Larson DW , et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204 (5) 956-962 , discussion 962–963
• 45 Ferrante M, D'Hoore A, Vermeire S , et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15 (7) 1062-1070
• 46 Hicks CW, Hodin RA, Bordeianou L. Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg 2013; 148 (7) 658-664
• 47 Pandey S, Luther G, Umanskiy K , et al. Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging?. Dis Colon Rectum 2011; 54 (3) 306-310
• 48 Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR. National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 2015; 58 (2) 199-204
• 49 Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9 (2) 98-103
• 50 Hong MK, Craig Lynch A, Bell S , et al. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis 2011; 13 (2) 171-176
• 51 Mathis KLPJ, Tiret E, Bemelman E , et al. Clinical effectiveness and outcome of diversion in refractory Crohn's colitis with and without perianal fistula. Dis Colon Rectum 2015; 58 (5) e166
• 52 Schaden D, Schauer G, Haas F, Berger A. Myocutaneous flaps and proctocolectomy in severe perianal Crohn's disease—a single stage procedure. Int J Colorectal Dis 2007; 22 (12) 1453-1457